
================================================================================
 CASE STUDY ANALYSIS - COMPREHENSIVE TEST (ALL 5 TABS)
================================================================================
  Drug: BARICITINIB
  Started: 2025-12-04 08:54:57.486197
  Output will be saved to: test_outputs\workflow_test_20251204_085457.txt

Initializing agent...
Agent ready.


================================================================================
 TAB 1: DRUG INFO FOR 'BARICITINIB'
================================================================================

  Drug Name:    baricitinib
  Generic Name: baricitinib
  Mechanism:    Janus Kinase Inhibitor
  Manufacturer: Eli Lilly and Company

  Approved Indications (4):
    1. adults with severe alopecia areata
    2. covid-19 in certain hospitalized adults
    3. adults with moderately-to-severely active rheumatoid arthritis
    4. moderately-to-severely active rheumatoid arthritis

--- Validation ---
  PASS: generic_name populated
  PASS: mechanism concise: 'Janus Kinase Inhibitor'
  PASS: Found 4 indications

================================================================================
 TAB 2: CASE SERIES SEARCH FOR 'BARICITINIB'
================================================================================

  Drug: baricitinib
  Exclude: ['adults with severe alopecia areata', 'covid-19 in certain hospitalized adults', 'adults with moderately-to-severely active rheumatoid arthritis']...

Searching... (may take 1-2 mins)

--- Results: 45 papers ---
  Full text (PMC): 22
  LLM verified: 45

  Diseases (37):
    - vitiligo: 3
    - atopic dermatitis: 3
    - juvenile idiopathic arthritis: 2
    - adult-onset Still's disease: 2
    - autoinflammatory interferonopathies: 2
    - systemic lupus erythematosus: 2
    - multiple dermatologic conditions: 1
    - dermatomyositis: 1
    - giant cell arteritis: 1
    - type I interferonopathies: 1
    - uveitis: 1
    - folliculitis decalvans: 1
    - SAPHO syndrome: 1
    - polymyalgia rheumatica and giant cell arteritis: 1
    - dystrophic epidermolysis bullosa: 1

--- Sample Papers ---

  1. Oral tofacitinib, baricitinib and upadacitinib monotherapy for steroid...
     PMID: 38853646 | Disease: vitiligo
     Full text: False
     Why: Prospective case series with patient outcomes for steroid-resistant vitiligo...

  2. Off-Label Use of Janus Kinase Inhibitors in Inflammatory Cutaneous Dis...
     PMID: 38051858 | Disease: multiple dermatologic conditions
     Full text: False
     Why: Case series with 6 patients across dermatomyositis, hidradenitis suppurativa, cu...

  3. JAK inhibitors in refractory dermatomyositis: A case series....
     PMID: 38887110 | Disease: dermatomyositis
     Full text: False
     Why: Retrospective cohort study of 14 patients with refractory dermatomyositis showin...

  4. Clinical experience and safety of Janus kinase inhibitors in giant cel...
     PMID: 37304255 | Disease: giant cell arteritis
     Full text: True
     Why: Retrospective case series of 15 GCA patients with baricitinib/tofacitinib showin...

  5. Janus Kinase Inhibitors in the Treatment of Type I Interferonopathies:...
     PMID: 35418997 | Disease: type I interferonopathies
     Full text: True
     Why: Case series assessing efficacy and safety of JAK inhibitors in type I interferon...

--- Validation ---
  PASS: Found 45 papers
  WARN: 2 potentially irrelevant papers
    - Janus kinase inhibition for the treatment of refra...
    - Pharmacokinetics, Pharmacodynamics, and Proposed D...

================================================================================
 TAB 3: DATA EXTRACTION (WITH PMC FULL TEXT)
================================================================================

  Extracting from 3 papers...
  (2 have PMC full text)

  1. [PMC] Clinical experience and safety of Janus kinase inhibito...
     PASS: Disease=Giant Cell Arteritis, N=15, Response=73.0%
     Efficacy: JAK inhibitors showed significant anti-inflammatory effects with reductions in C...
     Safety: Two patients experienced serious infections but JAK inhibitor therapy was retain...

  2. [PMC] Janus Kinase Inhibitors in the Treatment of Type I Inte...
     WARN: No data extracted

  3. [Abstract only] Oral tofacitinib, baricitinib and upadacitinib monother...
     WARN: No data extracted

--- Validation ---
  Successful: 1/3

================================================================================
 TAB 4: SCORING & PRIORITIZATION
================================================================================

  Scoring 1 extractions...

--- Scored Opportunities ---

  1. Giant Cell Arteritis
     Clinical:  7.5/10 (50% weight)
     Evidence:  8.7/10 (25% weight)
     Market:    5.0/10 (25% weight)
     TOTAL:     7.2/10

--- Validation ---
  Scored: 1/1

================================================================================
 TAB 5: FULL ANALYSIS SUMMARY
================================================================================

  Drug: baricitinib
  Mechanism: Janus Kinase Inhibitor
  Approved Indications: 4
  Papers Found: 45
  Papers with PMC Full Text: 22
  Extractions: 1

--- Top Off-Label Indications ---
    vitiligo: 3 papers
    atopic dermatitis: 3 papers
    juvenile idiopathic arthritis: 2 papers
    adult-onset Still's disease: 2 papers
    autoinflammatory interferonopathies: 2 papers
    systemic lupus erythematosus: 2 papers
    multiple dermatologic conditions: 1 papers
    dermatomyositis: 1 papers
    giant cell arteritis: 1 papers
    type I interferonopathies: 1 papers

--- Validation ---
  PASS: Full pipeline executed

================================================================================
 FINAL SUMMARY
================================================================================
  Tab 1 Drug Info:   PASS
  Tab 2 Search:      PASS (45 papers)
  Tab 3 Extraction:  PASS (1 successful)
  Tab 4 Scoring:     PASS (1 scored)
  Tab 5 Analysis:    PASS

  Total API Tokens: 37,965
  Completed: 2025-12-04 08:57:27.190756

  JSON data saved to: test_outputs\workflow_data_20251204_085457.json
